Endios Bio raised an undisclosed amount of funding to advance its first-in-class PEG10-targeted therapeutics for amyotrophic lateral sclerosis (ALS) and related neurodevelopmental disorders.
All entries for: Endios Bio
December 1, 2025
Endios Bio
Investment
Baton Rouge, LA
1-50 employees
Disease Area: Rare Diseases